Estudo metabólico com flúor-18-fluorodeoxiglicose no estadiamento e avaliação de massa residual ou recidiva no linfoma de Hodgkin by Pracchia, Luís Fernando et al.
121
CLINICS 2007;62(2):121-6
Hematology Unity, Hospital das Clínicas, São Paulo University Medical
School - São Paulo/SP, Brazil.
Nuclear Medicine Department, Heart Institute (INCOR), São Paulo
University Medical School - São Paulo/SP, Brazil.
Email: lupra73@uol.com.br
Received for publication on November 03, 2006.
Accepted for publication on November 24, 2006.
CLINICAL SCIENCES
METABOLIC TEST WITH FLUORINE-18-
FLUORODEOXYGLUCOSE IN STAGING AND
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Soares Junior, José Cláudio Meneghetti, Valeria Buccheri
Pracchia LF, Chaves AAR, Cerci JJ, Soares Jr. J, Meneghetti JC, Buccheri V. Metabolic test with fluorine-18-fluorodeoxyglucose
in staging and detection of residual tumor or recurrence in hodgkin lymphoma. Clinics. 2007;62(2):121-6.
OBJECTIVE: The metabolic test using 18F-fluorodeoxyglucose is a useful tool for the management of patients with Hodgkin
lymphoma, either for staging purposes or for the evaluation of suspicious masses that can frequently occur after treatment. The
aim of the present study was to investigate the value of the 18F-fluorodeoxyglucose test performed with a dual-head coincident
gamma camera (CGC-PET with fluorodeoxyglucose) for the staging and the detection of residual tumor of patients with Hodgkin
lymphoma.
METHODS: Thirty-eight consecutive patients were included in this retrospective study; the metabolic test comprising CGC-
PET with FDG was done in 18 patients for staging work-up (Group 1), and the results were compared to conventional clinical
staging procedures that included computed tomography scans and bone marrow biopsy. The remaining 20 patients were evaluated
with CGC-PET with fluorodeoxyglucose due to the presence of residual masses or a new lesion (Group 2).
RESULTS: The 18F-Fluorodeoxyglucose metabolic test, CGC-PET with fluorodeoxyglucose, upstaged 5 (27%) of the Group 1
patients and detected more lesions (45) than conventional methods of staging (33). Of the 20 patients in Group 2, 11 had positive18F-
fluorodeoxyglucosetests, and a viable tumor was confirmed in 9 patients. Regarding the 9 patients with negative fluorodeoxyglucose
metabolic tests, the 1-year probability of recurrence was 11.8%. The sensitivity, specificity, positive predictive value, negative
predictive value, and accuracy of the CGC-PET with fluorodeoxyglucose test were 90%, 80%, 82%, 89%, and 85% respectively.
CONCLUSIONS: The metabolic test comprising CGC-PET with fluorodeoxyglucose had a higher diagnostic accuracy than
conventional methods in the staging of Hodgkin lymphoma and thus is a valuable noninvasive tool for the diagnosis of suspicious
lesions.
KEYWORDS: Fluorodeoxyglucose (FDG). PET. Hodgkin lymphoma. Staging.
INTRODUCTION
Throughout the past two decades, the prognosis of
Hodgkin lymphoma (HL) has greatly improved due to ear-
lier diagnosis and accurate staging of the disease, which
has facilitated a better therapeutic approach. At the time
of writing, HL has an excellent outcome that varies accord-
ing to its clinical stage. Long-term survival of about 90%
is observed in the earlier stages and up to 75% in the ad-
vanced stages of the disease.1
The Ann-Arbor staging system (AAS) modified at the
Cotswolds meeting 2 is used to define the conventional
clinical stage (CS) of HL. The AAS categorizes HL into 4
distinct stages according to the number and location of the
involved sites. The CS is obtained by clinical examination,
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computed tomography (CT) of cervical, thoracic, abdomi-
nal and pelvic regions, and bilateral bone marrow biopsy.
Although CT is an imaging technique that can evidence
anatomic details, featuring important information about the
relationship between organs and vascularity, the detection
of nodal disease is based only on morphological criteria.
Based on AAS criteria, a lymph node that is greater than
1.5 cm in its longest transverse diameter should be con-
sidered involved by HL, but studies in which pathological
staging was performed have demonstrated that the size of
the lymph nodes is not always related to the presence of
HL.3 Additionally, CT has a limited sensitivity for the de-
tection of disease in the spleen, liver, and bone marrow.
Therefore, the CS can be equivocally under- or overesti-
mated, leading to insufficient or disproportionately aggres-
sive therapy, respectively. Therefore, precise methods for
determining the extent of the disease are essential for the
best treatment choice.
In recent years, the metabolic test with fluorine-18-
fluorodeoxyglucose (FDG) has proved to be a useful tool
in the management of many malignancies, including HL.
Fluorine-18-fluorodeoxyglucose, a radiopharmaceutical
glucose analogue labeled with the positron emitter, 18Fluor,
accumulates in tissues with high metabolic activity. Be-
cause HL tumor cells use glucose at abnormally high rates,
the metabolic test with FDG can demonstrate in a single
scan all sites involved by the disease, independent of the
size and location.
Positron emission tomography (PET) with FDG, the
most used technique in the USA and Europe, has high sen-
sitivity and specificity when compared with CT and bone
marrow biopsy.4–8 Also, FDG-PET is used in the investiga-
tion of residual masses, which are present in up to 60% of
patients at the end of treatment, and in the evaluation of
new lesions that appear after treatment.9–11 In these cases,
the confirmation of the presence of viable tumor cells is
fundamental for therapeutical decisions. The histopatho-
logical assessment of suspected sites is the gold-standard
method for detection of residual tumor, but tissue biopsy
is not a risk-free procedure, especially when mediastinal
and abdominal lesions must be evaluated. In cases for
which surgical diagnosis is impossible, the presence of lym-
phoma can be confirmed only by serial physical examina-
tion and/or CT. Thus, the diagnosis is confirmed only when
a tumor progresses and the suspected lesions increase in
size, delaying the beginning of a new therapy and decreas-
ing the chances of cure.
Despite its value, dedicated PET equipment is not avail-
able on a large scale in Brazil, which precludes its appli-
cation in our country. An alternative method of metabolic
testing with FDG is the use of a dual-head coincident
gamma camera device (CGC-PET) instead of a dedicated
PET device. Both systems have almost the same spatial
resolution (4-5 mm). The larger size of the gamma cam-
era provides an increase of about 2.5 times in the axial field
of view. However, the dedicated systems have an advan-
tage in measured sensitivity by a factor of 8 to 12 over hy-
brid systems. This difference in sensitivity translates into
difficulty in reliably detecting lesions smaller than 15-20
mm in diameter by the CGC-PET equipment.
The aim of this study was to investigate the role of the
metabolic test with FDG, CGC-PET with FDG, in staging
and in the evaluation of HL patients with residual masses
or new suspicious lesions.
MATERIALS AND METHODS
Patients. From December 1999 to September 2002, 38
consecutive unselected patients with HL were eligible for
this retrospective study. Lymph node biopsies were obtained
from all patients, and the diagnosis was completed accord-
ing to the criteria established by the WHO classification.
Eighteen patients were submitted to a baseline metabolic
test using CGC-PET as part of the staging procedures, be-
fore any therapeutic approach (Group I). The remaining 20
patients were evaluated with FDG scanning due to the pres-
ence of residual masses or a new lesion found on CT or
physical examination (Group II).
Metabolic test technique. All metabolic tests were per-
formed using a dual-head coincident gamma camera (CGC-
PET) device (Vertex Plus MCD/AC, ADAC Laboratories,
Milpitas, CA). Patients were instructed to fast for 12 hours
before CGC-PET scanning. Scans from the skull through
the mid thigh were acquired 1 hour after the intravenous
injection of 185-370 MBq (5 - 10 mCi) of FDG. Topo-
graphic slices of 4 mm in the axial, sagittal, and coronal
planes were reconstructed. The results were interpreted by
the same team of specialists (at least 2 nuclear physicians).
Focal areas with abnormal uptake of FDG were considered
to represent lymphoma involvement.
Conventional staging (CS) of patients (Group I). All
18 patients of Group I underwent conventional staging (CS)
procedures that included CT (cervical, thoracic, abdomen,
and pelvic) and bone marrow biopsy. Conventional stag-
ing was performed according to Ann Arbor stage (AAS)
criteria.2
Definition of residual mass/relapse in Group II. A re-
sidual mass was defined as the persistence of a lesion
greater than 1.5 cm in its longest transverse diameter lo-
calized in a previously involved site observed after the end
of treatment. Possible relapse was defined as the appear-
ance of a new lesion of at least 1.5 cm at its longest trans-
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verse diameter observed at any time after complete remis-
sion. Suspicious relapse lesions were detected by physical
examination and/or CT.
Follow-up after CGC-PET with FDG in Group II.
After the CGC-PET with FDG procedure, all patients of
Group II were evaluated every 2 months with physical ex-
amination and laboratory analysis, every 4 to 6 months with
CT. The presence of active HL was confirmed by biopsy
of the suspected lesion or evident clinical progression of
disease, defined as an increase of more than 25% of long-
est transverse diameter of the suspicious lesion, according
to ASS criteria.2 In all patients, the interval between the
CGC-PET with FDG procedure and the confirmation of re-
currence or loss to follow-up was obtained. The patients
with confirmed active disease were treated with chemo-
therapy according to institutional protocols.
Data analysis. In Group I patients, CS was compared
to the staging obtained by CGC-PET with FDG. Further-
more, the number of involved sites in the cervical, thoracic,
abdominal-pelvic, and bone regions observed by the two
methods were also compared. A concordance rate of CGC-
PET with FDG to CS was calculated using CS as the ref-
erence.
In patients of Group II, those with a positive scan and
with lesions confirmed by biopsy or clinical progression
of disease were considered true positives. Patients with a
negative scan and no evidence of clinical progression dur-
ing follow-up were considered true negatives. Sensitivity,
specificity, positive predictive value, negative predictive
value, and accuracy were calculated. For patients with a
negative CGC-PET scan, the 1-year probability of recur-
rence was calculated by the Kaplan-Meier method.
RESULTS
Patients
Thirty-eight patients (18 male and 20 female) were
evaluated. The median age was 29 years (range, 17-50
years), and nodular sclerosis was the most frequent histo-
logical type observed (Table 1).
Group I
Of the 18 patients staged by CS, 3 (17%) were classi-
fied as stage I, 4 (23%) as stage II, 3 (17%) as stage III,
and 8 (43%) as stage IV. Of the patients staged using CGC-
PET with FDG, 1 (6%) was classified as stage I, 4 (22%)
as stage II, 2 (11%) as stage III, and 11 (61%) as stage IV
(Table 2).
Agreement between both methods was observed in 13
(73%) of the 18 patients and discordant results were ob-
tained in 5 (27%) patients. In all discordant cases CGC-
PET with FDG resulted in upstaging (Figure 1).
Table 1 - Patient Characteristics
Age Median 29
Range 17-50
Male gender 18 (47%)
Histological type nodular sclerosis 24 (63%)
mixed cellularity 08 (21%)
others 07 (16%)
B Symptoms 15 (40%)
Table 2 - Conventional staging (CS) versus staging using
CGC-PET with FDG*
CS
I II III IV
CGC-PET I 1 0 0 0
with FDG II 1 3 0 0
III 0 1 1 0
IV 1 0 2 8
* Number of patients observed accordingly to CGC-PET with FDG stage
(rows) and CS (columns).
Figure 1 - Staging with CGC-PET with FDG. A 23 year-old female, who
after physical examination, CT and bone marrow biopsy was regarded as
having stage I disease (only right cervical lymph nodes enlargement). CGC-
PET (coronal plan) demonstrated abnormal glucose metabolism (black
arrows) in right cervical region, spleen, liver and lumbar spine (stage IV
disease). Staging laparotomy confirmed the presence of disease in the
abdominal sites (spleen and liver).
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When the involved sites were evaluated, CGC-PET with
FDG detected more lesions than CS performed with CT and
bone marrow biopsy (Table 3). Only 1 patient had enlarged
lymph nodes in the abdominal region detected by CT that
were not avid to FDG.
Group II
Of the 20 Group II patients, 5 (25%) had a suspicious
lesion on the cervical region, 13 (65%) in the thoracic re-
gion, and 2 (10%) in the abdominal region.
Eleven (55%) patients had positive CGC-PET scans.
During a median follow-up of 26 months (range, 4-38
months), 7 (64%) of the 11 patients had disease confirmed
by biopsy and 2 (18%) by clinical progression. Two other
patients with positive scans underwent surgical excision of
the suspected lesion. Pathologic evaluation showed only
thymic hyperplasia without tumor involvement. These pa-
tients did not have any new evidence of disease through
the last follow-up and were considered as false-positive
cases.
Of the 9 patients with a negative CGC-PET scan, 8 (89%)
did not relapse during follow-up (Figure 2). Only 1 patient
had a recurrence confirmed by biopsy 3 months after the
exam and was considered a CGC-PET with FDG false-nega-
tive. The 1-year probability of recurrence for CGC-PET with
FDG-negative patients was 11.8%. The results of CGC-PET
with FDG scanning and disease status during follow-up for
all patients are summarized in Table 4.
The sensitivity, specificity, positive predictive value,
negative predictive value, and accuracy of CGC-PET with
FDG were 90%, 80%, 82%, 89%, and 85% respectively.
DISCUSSION
Imaging with FDG has been increasingly used in the
management of oncology patients and relies on the detec-
tion of metabolic alterations observed in cancer cells in-
stead of detection of anatomical abnormalities. Fluorine-
18-fluorodeoxyglucose, a glucose analog, is taken up by
metabolically active cells using a facilitated transport
mechanism similar to that for glucose by means of the glu-
cose transporters proteins. Subsequently, FDG undergoes
phosphorylation to FDG-6-phosphate by hexokinases, and
unlike glucose, it is not efficiently dephosphorylated by glu-
cose-6-phosphatase (G6P); as a consequence, FDG-6-phos-
phate accumulates within the cell.
Malignant cells have an augmented glycolytic activity
due to an increase in the membrane glucose transporters
and in some of the glycolytic enzymes, such as hexokinase,
as well as markedly low levels of G6P. These features lead
to a higher accumulation of FDG in tumor cells. Particu-
larly in HL, the glycolic activity and the avidity for FDG
are substantially higher than in normal tissue.12
The advantage of FDG-associated imaging relative to
CT is the ability to detect disease in sites without struc-
tural anatomical changes. Even in small-volume tumors,
in which the number of neoplastic cells is insufficient to
disrupt the normal anatomic architecture, the malignant cell
metabolic activity can be demonstrated. Therefore, the pres-
ence of viable tumor cells can be detected before any in-
crease in the volume of the affected organ.
Several studies have investigated the role of FDG for
the staging of lymphoma patients. Most of these studies,
using dedicated PET devices,4–8 compared the performance
of FDG-PET with CS obtained by conventional methods,
showing concordant results in 60% to 80% of cases, with
upstaging rates ranging from 18% to 40%. The use of FDG
with dual-head hybrid gamma cameras modified to recog-
nize coincidence photons (CGC-PET) has been used as an
alternative of dedicated PET devices. In the present study
using CGC-PET technology, the results were similar to the
ones observed with PET equipment. It is important to em-
phasize that biopsy confirmation of all FDG-avid lesions
Table 4 - CGC-PET with FDG and disease status
Disease
Present Absent
CGC-PET with FDG Positive 9 2
Negative 1 8
Table 3 - Number of involved sites by anatomic region
Cervical Thoracic Abdominal Bone
CS 12 11 8 2
CGC-PET with FDG 15 14 9 7
Total 15 14 10 7
Figure 2 - Residual mass evaluated by CGC-PET with FDG. Panel A –
Thoracic CT with evidence of residual mass on mediastinal area (white arrow)
observed after the treatment in a 32-year-old female. Panel B – CGC-PET
(coronal plane) of the same patient without any foci of abnormal glucose
metabolism in the mediastinal area.
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is unfeasible from the ethical and practical view; therefore,
the true sensitivity and specificity of FDG-associated
imaging for the staging of HL, performed with either PET
or CGC-PET devices, is impossible to evaluate.
In our study using CGC-PET with FDG, 27.8% of the
patients were up-staged when compared to conventional CS
methods. Even in the cases in which the CGC-PET scan
did not change the stage of the disease, CGC-PET with
FDG was able to detect more involved sites per region, re-
sulting in a better evaluation of the disease extent.
Two other groups have evaluated CGC-PET with FDG
for staging of lymphomas. Tatsumi et al13 evaluated 30 pa-
tients with non-Hodgkin lymphoma, resulting in a concord-
ance rate of CGC-PET with FDG and CT of 63%, with
CGC-PET with FDG detecting more involved sites than CT.
Similarly, Pichler et al,14 in a study with 28 patients with
HL and non-Hodgkin lymphoma, observed that CGC-PET
with FDG detected more involved lesions than CT (100
versus 77, respectively).
In addition to staging, the metabolic test with FDG can
be a useful diagnostic tool in the evaluation of residual
masses observed after treatment. The challenge in this set-
ting is the detection of tumor activity before the progres-
sion of disease, with minimum related morbidity. The use
of FDG-PET has been evaluated by several authors9–11 to
determine the diagnostic accuracy of PET, with observed
negative predictive values ranging from 81% to 100%, and
first-year relapse rates for patients with a negative PET
ranging from 95% to 100%, but there are no studies using
CGC-PET with FDG for this purpose as far as we know.
In the present study, using CGC-PET technology, a method
that has the advantage of being cheaper and more avail-
able in our country, the results observed were similar to
those with the dedicated PET equipment. Additionally,
more than 60% of the patients with a positive CGC-PET
scan had histological confirmation of viable tumor cells in
the suspected lesion. The 2 patients with a false-positive
CGC-PET scan had thymic hyperplasia, a condition com-
monly encountered after chemotherapy for HL that can lead
to false-positive scans, as previously reported with the use
of dedicated PET devices.9–11
We concluded that although CGC-PET has a worse spa-
tial resolution than dedicated PET with limitations in the
detection of lesions smaller than 15 to 20 mm,15 the CGC-
PET with FDG technique as performed in this study has
high sensitivity and specificity; therefore, it is a useful
noninvasive tool for staging and evaluation of residual
masses or recurrence of Hodgkin lymphoma.
RESUMO
Pracchia LF, Chaves AAR, Cerci JJ, Soares Jr. J,
Meneghetti JC, Buccheri V. Estudo metabólico com flúor-
18-fluorodeoxiglicose no estadiamento e avaliação de
massa residual ou recidiva no linfoma de Hodgkin. Clin-
ics. 2007;62(2):121-6.
OBJETIVO: O estudo metabólico com 18F-fluorodeoxi-
glicose é uma ferramenta útil para o manejo de portadores
de linfoma de Hodgkin, tanto como método auxiliar no
estadiamento da doença, quanto na avaliação de massas
suspeitas encontradas após tratamento. O objetivo deste
estudo foi investigar o valor do estudo com 18F-
fluorodeoxiglicose em gama câmara híbrida no estadia-
mento e na detecção de tumor residual em pacientes com
linfoma de Hodgkin.
MÉTODOS: Trinta e oito pacientes foram incluídos neste
estudo retrospectivo, 18 foram avaliados com o estudo
metabólico durante o estadiamento (Grupo 1), sendo os
resultados do estudo comparados com os obtidos com o
estadiamento convencional, que incluiu tomografia e
biópsia de medula óssea. Os 20 pacientes restantes
realizaram o estudo metabólico devido à presença de massa
residual ou de nova lesão suspeita (Grupo 2).
RESULTADOS: O estudo metabólico aumentou o estádio
de cinco (27%) dos pacientes do Grupo 1 e pôde detectar
mais lesões que os métodos convencionais de estadiamento
(45 lesões detectadas com 18F-fluorodeoxiglicose versus
33 lesões métodos convencionais). Nos 20 pacientes do
Grupo 2, 11 foram 18F-fluorodeoxiglicose positivos e
tumor viável foi confirmado em 9 pacientes. Nos 9
pacientes com estudo metabólico negativo, a probabilidade
de recidiva em um ano foi de 11.8%. A sensibilidade,
especificidade, valor preditivo positivo, valor preditivo
negativo e a acurácia do estudo metabólico foram de 90%,
80%, 82%, 89% e 85% respectivamente.
CONCLUSÕES: O estudo com 18F-fluorodeoxiglicose
apresentou melhor acurácia que os métodos convencionais
de estadiamento do Linfoma de Hodgkin e foi útil para o
diagnóstico não-invasivo de lesões suspeitas.
UNITERMOS: Fluorodeoxiglicose (FDG). Tomografia por
emissão de pósitrons. Linfoma de Hodgkin (LH).
Estadiamento de neoplasias.
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